X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
ALN-AGT01 (zilebesiran) investigational, subcutaneously administered RNAi therapeutic targeting angiotensinogen in development for the treatment of hypertension in high unmet need populations.
Lead Product(s): Zilebesiran,Olmesartan Medoxomil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ALN-AGT01
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2024
Details:
ALN-AGT01 (zilebesiran) is an investigational, subcutaneously administered RNAi therapeutic targeting angiotensinogen. It is being evaluated in combination with standard of care for the treatment of hypertension.
Lead Product(s): Zilebesiran,Olmesartan Medoxomil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ALN-AGT01
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
Under the partnership, Roche and Alnylam will co-develop and co-commercialise RNAi therapeutic ALN-AGT01 (zilebesiran), an investigational RNAi therapeutic currently in Phase 2 for the treat hypertension in patients with high cardiovascular risk.
Lead Product(s): Zilebesiran,Olmesartan Medoxomil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ALN-AGT01
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: $310.0 million
Deal Type: Partnership July 24, 2023
Details:
A generic combination is approved consisting of olmesartan medoxomil which blocks the vasoconstrictor effects of angiotensin II in vascular smooth muscle and hydrochlorothiazide is a diuretic that inhibits sodium chloride transport in the distal convoluted tubule.
Lead Product(s): Olmesartan Medoxomil,Hydrochlorothiazide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Benicar HCT-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2023
Details:
The agreement outlines a transition period during which Daiichi Sankyo and Cosette will transfer responsibilities for the manufacture and commercialization of Azor, Benicar, Effient and other products, including quality assurance, pharmacovigilance and regulatory matters.
Lead Product(s): Amlodipine,Olmesartan Medoxomil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Azor
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cosette Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Divestment January 18, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
